Hong Kong is taking significant strides in transforming its pharmaceutical landscape through an innovative drug approval mechanism that promises to accelerate access to critical treatments for patients with serious and rare diseases. The recently introduced “1+” system represents a strategic approach to streamlining drug registration, with potentially far-reaching implications for healthcare and insurance industries.
On August 28, 2023, Hong Kong marked a milestone by approving three new drugs under this mechanism, bringing the total number of approved drugs to 14. These groundbreaking treatments target specific challenging medical conditions: thyroid eye disease, recurrent or metastatic cervical cancer, and severe hemophilia A or B. Each drug offers hope to patients who previously had limited treatment options.
The “1+” mechanism, set to be fully implemented in November 2023, fundamentally reimagines the drug approval process. Unlike traditional approaches that require multiple regulatory reviews, this system allows a new drug to be registered in Hong Kong if it meets specific criteria. Key requirements include providing local clinical data, receiving approval from local experts, and being endorsed by at least one reference drug regulatory agency.
In the case of the three recently approved drugs, the US drug regulatory agency served as the reference point. After a comprehensive review and consultation with local experts, the Registration Committee under the Pharmacy and Poisons Board of Hong Kong confirmed that these medications meet rigorous safety, efficacy, and quality standards.
The mechanism’s potential is set to expand dramatically by November 2024, when it will encompass all new drugs—including those with novel pharmaceutical or biological components, new drug indications, vaccines, and advanced therapy products. This expansion signals a significant shift in Hong Kong’s approach to pharmaceutical innovation and patient access.
Already, five of the 14 drugs approved under this mechanism have been included in the Hospital Authority’s drug list, indicating their accessibility through public healthcare services. The mechanism has generated substantial interest, with over 160 pharmaceutical companies and more than 620 inquiries from local and international firms, including those from mainland China.
For patients and insurance providers, this development represents a promising evolution in healthcare coverage. The streamlined approval process means faster market entry for cutting-edge treatments, potentially reducing waiting times for critical medications. Insurance plans may need to adapt, expanding coverage to include emerging therapies for conditions like thyroid eye disease, cervical cancer, and hemophilia.
The Department of Health’s proactive approach suggests a commitment to improving patient outcomes by reducing bureaucratic barriers to innovative treatments. By simplifying the registration process without compromising safety standards, Hong Kong is positioning itself as a forward-thinking healthcare market.
For individuals managing serious or rare diseases, the “1+” mechanism offers renewed hope. The potential for quicker access to advanced treatments could significantly impact patient experiences and treatment trajectories. Insurance providers, meanwhile, are presented with an opportunity to develop more comprehensive and responsive healthcare plans.
As the pharmaceutical landscape continues to evolve, the “1+” mechanism stands as a testament to Hong Kong’s commitment to medical innovation and patient-centered healthcare. By prioritizing efficiency without sacrificing rigorous evaluation, the city is creating a model that could inspire similar approaches in other regions.
